Products and Services

Products and Services


Standard pharmaceutical downstream extraction and purification process involves the utilization of various chromatographic techniques [high-performance liquid chromatography (HPLC), reversed-phase chromatography (RPC), stationary phase chromatography (SPC), absorption chromatography (AC), and in size-exclusion chromatography (SEC)], using organic volatile solvents and buffer solutions, that are costly. However, within these techniques, solvents/buffers and the host cell protein also get carried through these standard methods of purification and often are found present in the finished API. This is due to lack of sensitivity/selectivity and slow rates of differential transport in to cause separation of similarly sized molecules in conventional separation processes, as well as the harsh conventional chemical purification process methods.

These conventional methods often hinder the overall effectiveness and quality of the final protein concentration in the finished API, due to the inability to purify the APIs to the requirements in a single step, as well as affect process lead time.

Graphene membrane-based separation filtration has become the focus of biopharmaceutical process development since they are simple to operate, modular, and compact, consume significantly less energy than distillation or solvent evaporation, allow for high rate processing, and improved process efficiencies (require fewer resources, equipment, and manpower) and they can yield a good quality of small and large API’s (due to their size exclusion abilities within isolation, separation, and purification processes).

Graphene Cannus Majors CanisMajor Membrane Technology  (GCMMT) allow for large, small, and HP API’s drug isolates can be purified and separated from unwanted low molecular impurities through a series of facile series of membranes within the tailor-made, precise pore controlled molecular membrane size-exclusion range from 0.5 to 5nm (this range is going to be expanded as we go along) for targeted API purification. In comparison to the above discussed conventional methods of purification, graphene membranes allow for precise molecular sieving based on size exclusion, allowing for accessing the ultimate limit of separation technologies and the near-complete elimination of unwanted impurities from small and large API’s and allow for high purity API production. Furthermore, they don’t require any additional volatile solvents and other costly purification conventional methods operating costs.

Overall, our combined (GCMMT) graphene machinery, proprietary processing methodology, and specialized membranes allow for the effective production of highly valued biochemically pure HPAPIs, with superior physical and chemical stability, since the nanofiltration ranges of our graphene processing allow for the near-complete exclusion of all low molecular impurities.


COVID-19 Vaccine

In order to produce the vaccine host cells are grown in a series of bioreactors of increasing scale and are infected with the virus seed.

Pfizer and Moderna Covid vaccines are both messenger RNA vaccines, which means these vaccines express one or more protein genes from Covid  surface proteins, which the body recognizes as foreign and so stimulates the immune system in a similar way to an infectious agent, without causing disease.

Within these manufacturing process the Covid messenger RNA (final vaccine) needs to be separated out from the bioreactor mix impurities which consists of host cells, viral seeds, nutrient media growth factors, undesired proteins, clipped mRNA etc, for it to be considered safe for administration without side effects and be considered chemically pure.

Should any of these impurities remain behind drastic genetic alterations, mutations and severe unwanted side effects could occur in humans when administered.

Currently, various filtration and chromatography steps are taken to harvest and purify the vaccine. These filtration processes utilize dialysis and ultrafiltration which range from 1.5 to 12nm pore size exclusion capabilities and as noted above these membranes do carry numerous disadvantages.

Our graphene membranes have a filtration size-exclusion capacity of 0.5 to 5nm will allow for the removal of all impurities, thus the ability to exclude the live virus seeding, host cells, as well as be able to isolate the final mRNA vaccine far more accurately to ensure high quality and chemically pure protein vaccines are produced, with higher efficiency is possible. In our current times of questionable consistency and quality of this vaccine, our graphene membranes are in dire need, as well as supercritical to be introduced into these manufacturing plants.


The processing of water has remained relatively unchanged for many years; the
introduction of the hollow fiber or an ultra-membrane technology such as reverse osmosis has moved water filtration forward. However, the permeance or flux of current membranes is still low, requiring large membrane areas that can be prohibitively costly.

The vast amounts of energy required to run a medium or large-scale desalinization plant can be as high as 2-3% of the energy consumed by a small country. These plants currently require a substantial electrical infrastructure to operate reliably.

There is a need within the desalination market to utilize advanced materials in order to pioneer new methods of manufacturing and processing that will improve performance and reduce costs. The materials currently available on the market are limited and have numerous shortcomings. Utilizing groundbreaking materials allows for the development of innovative methods and materials that hold value for many years to come. Graphene Hive’s desalination membrane will have significant improvements over existing membranes. Our membranes will have scientifically documented innovative properties and attributes, making them a world-first for the industry. The membrane can be specifically designed for the various water conditions that affect the incoming flow, performance, and lifespan. A water plant will be able to improve on the volume and output of filtered water. We anticipate being able to reduce the downtime required for the replacement of filters. Our membranes would require less frequent replacements and are subject to reduced fouling, increasing production, and lowering costs. For water plants to change over and upgrade to this new technology the process is simplified, rapid, and requires limited major infrastructure.

Our Graphene-based membranes are efficient and allow the water molecules to pass through with lower resistance, requiring less pressure and preliminary processing, lowering energy usage. We anticipate a 30% to 55% reduction in electrical consumption within water plants utilizing our membrane. These significant factors make our products highly attractive to most desalination plants around the world.

Product Highlights


Reducing overall drug and extractions costs. Creating access to essential medication to low-income patients, impacting the health and longevity of these individuals.


Our manufacturing processing allows for moving conventional heat-driven extraction and purification processes to mechanical pumping that is 90% more energy-efficient, reducing the amount of pollution created in manufacturing and the cost of energy consumed for this processing. This energy, green processing will need to become the future of all production.


A rapid removal of impurities using precise molecular sieves producing high purity and potent API's. The increasing efficiency and lower production time, and higher quality enhance the shelf life and helps reduce drug supply shortages. 


Reducing/removing the use of volatiles in API extraction is beneficial to the production of the final product as well as having no residual chemical contaminants; this also reduces volatile gas pollution that escapes into the air as well as water systems (Ref CA Prop 65) protecting the immediate environment and keeping the ecosystem in balance. This will also positively affect air quality as; volatiles promotes carbon dioxide build-up reducing the earth's ozone layers.


Our ability to provide higher purity extracts is vital since it reduces further costs from downstream processing.


Improved vaccine production through our processing, including the isolation of mRNA, providing consistently accurate proteins for vaccines production in Covid 19 and other life-threatening viruses and diseases found in impoverished countries.